Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 blockade, have been successfully applied in the clinical treatment of melanoma, non-small cell lung cancer (NSCLC) and other malignant tumors [1, 2]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.